Arcturus Therapeutics Holdings is a U.S.-based RNA medicines company focused on developing nucleic-acid therapeutics and related delivery technology. Its platform capabilities include messenger RNA, self-amplifying RNA and lipid-mediated delivery, supported by manufacturing and formulation expertise. The company is based in San Diego, California, and trades on Nasdaq under ARCT. Research efforts address liver-related genetic conditions, respiratory diseases and other opportunities for RNA-based medicines. Its platform also has relevance to vaccine applications. This entry concentrates on company identity, technology and broad therapy areas, rather than tracking every clinical study or commercial arrangement.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Arcturus Therapeutics Holdings is a U.S.-based RNA medicines company focused on developing nucleic-acid therapeutics and related delivery technology. Its platform capabilities include messenger RNA, self-amplifying RNA and lipid-mediated delivery, supported by manufacturing and formulation expertise. The company is based in San Diego, California, and trades on Nasdaq under ARCT. Research efforts address liver-related genetic conditions, respiratory diseases and other opportunities for RNA-based medicines. Its platform also has relevance to vaccine applications. This entry concentrates on company identity, technology and broad therapy areas, rather than tracking every clinical study or commercial arrangement.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Develops the LUNAR lipid delivery and STARR self-amplifying mRNA platforms. KOSTAIVE is an approved sa-mRNA COVID-19 vaccine.
Business, technology & evidence
Kostaive is a self-amplifying mRNA vaccine that received EU marketing authorization on 2025-02-12.
Arcturus Therapeutics Holdings is a U.S.-based RNA medicines company focused on developing nucleic-acid therapeutics and related delivery technology. Its platform capabilities include messenger RNA, self-amplifying RNA and lipid-mediated delivery, supported by manufacturing and formulation expertise. The company is based in San Diego, California, and trades on Nasdaq under ARCT. Research efforts address liver-related genetic conditions, respiratory diseases and other opportunities for RNA-based medicines. Its platform also has relevance to vaccine applications. This entry concentrates on company identity, technology and broad therapy areas, rather than tracking every clinical study or commercial arrangement.
SecuritiesNasdaq: ARCT
Program / service
Target / indication
Representative stage
Evidence & scope
KOSTAIVE
Project-dependent / not verified · Project-dependent / not verified
Approved (KOSTAIVE)
Regulatory validation applies to the named vaccine and should not be extended to other programs.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Arcturus reported interim Phase 2 findings for ARCT-810 in ornithine transcarbamylase deficiency, including lower or maintained-normal fasting ammonia and reduced glutamine, with generally favorable tolerability. The company plans to incorporate next-generation ARCT-2601 into an amended protocol near year-end. Separately reported large expression gains for its new delivery platform came from nonhuman-primate studies, not comparative human efficacy data.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
